Rhythm Pharmaceuticals (RYTM) Receivables (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Receivables data on file, last reported at $34.2 million in Q1 2026.

• On a quarterly basis, Receivables rose 91.82% year-over-year to $34.2 million in Q1 2026; TTM through Mar 2026 was $34.2 million, a 91.82% increase from a year earlier, with the FY2025 full-year figure at $26.1 million, up 40.89% from the prior year.
• Receivables for Q1 2026 stood at $34.2 million, up from $26.1 million in the prior quarter.
• Over the last five years, Receivables for RYTM reached as high as $34.2 million in Q1 2026 and fell as low as $80.0 in Q4 2022.
• Historically, Receivables has averaged $15.6 million across 5 years, with a median of $14.9 million in 2023.
• Across the five-year window, Receivables sank 99.99% in 2022 and soared 18583650.0% in 2023, its largest moves.
• Year by year, Receivables stood at $80.0 in 2022, then surged by 18583650.0% to $14.9 million in 2023, then climbed by 24.52% to $18.5 million in 2024, then soared by 40.89% to $26.1 million in 2025, then soared by 31.1% to $34.2 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $34.2 million in Q1 2026, $26.1 million in Q4 2025, and $33.0 million in Q3 2025.